前列腺癌的进展依赖于线粒激酶和激酶
Chitra Rawat1, Salma Ben-Salem1, Nidhi Singh1
1Department of Cancer Biology, Cleveland Clinic, Cleveland, Ohio.
Cancer research
|October 6, 2023
概括
激酶 (CIT) 通过调节细胞分裂来驱动前列腺癌的生长和治疗耐药性. 抑制CIT激酶活性显示出对攻击性和耐性前列腺癌的治疗潜力.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 生物化学 生物化学
背景情况:
- 前列腺癌是男性癌症死亡的主要原因.
- 了解前列腺癌细胞分裂机制对于克服治疗耐药性至关重要.
- 激酶 (CIT) 是一种涉及细胞循环调节的线性AGC家族蛋白激酶.
研究的目的:
- 研究酸酶 (CIT) 在前列腺癌生长和进展中的作用.
- 为了确定CIT激酶活性是否是前列腺癌的潜在治疗标.
- 确定CIT基质及其在侵袭性和耐治疗性前列腺癌中的作用.
主要方法:
- 在前列腺癌组织和细胞系中分析CIT表达.
- 研究CIT沉默对前列腺癌细胞和异种移植生长的影响.
- 在临床前模型中评估一种CIT激酶抑制剂 (OTS-167) 的疗效.
- 使用in vivo方法识别CIT基质.
主要成果:
- 在前列腺癌中,CIT过度表达,与瘤生长和侵袭性进展相关.
- 过度表达CIT是由E2F2-Skp2-p27信号轴调节的,并赋予了对抗雄激素剥夺疗法的抵抗力.
- CIT静音可以抑制前列腺癌的生长,而不会影响正常细胞,这表明治疗窗口.
- 多酶抑制剂OTS-167强烈抑制了CIT酶的活性,并减少了耐治疗的前列腺癌细胞和器官的增殖.
- CIT调节各种细胞功能,包括增殖和替代拼接,这些功能在耐治疗瘤中得到了丰富.
结论:
- 激酶 (CIT) 是前列腺癌进展和治疗耐药性的关键,可用药物的驱动因素.
- 通过像OTS-167这样的抑制剂准CIT激酶活性,为侵袭性和耐性前列腺癌提供了一个有前途的治疗策略.
- CIT的多样化的基质调控突出了其在侵袭性前列腺癌的特征中的核心作用.
相关概念视频
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
M-Cdk Drives Transition Into Mitosis
5.6K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.6K
Tumor Progression
6.3K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.3K
MAPK Signaling Cascades
5.6K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.6K
Positive Regulator Molecules
5.5K
Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
5.5K
PI3K/mTOR/AKT Signaling Pathway
3.6K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.6K


